Nachrichten Nachrichten Nachrichten

Nachrichten

Pressemitteilungen filtern
Portfolio

Gimv sells majority stake in ALT Technologies to CCL Industries

Portfolio

Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors

Portfolio

Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases

Portfolio

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD

Portfolio

Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio

Portfolio

Cegeka strengthens Board of Directors to accelerate growth and international expansion

Portfolio

Biotalys Receives Regulatory Approval by U.S. EPA for EVOCA

Portfolio

Gimv joins forces with CNP to accelerate the global expansion of Equine Care Group

Corporate

Solid growth performance in the first half of FY 2025

Portfolio

Gimv partners with Quality Guard to establish a leading software platform for food safety compliance across Europe

Portfolio

EPA Issues Proposed Registration Decision for Biotalys’ EVOCA™ Biofungicide

Portfolio

Gimv Life Sciences realizes successful exit with the sale of its stake in Imcheck Therapeutics to Ipsen

36 von 615 Ergebnissen

Kontaktinformation

Pressekontact

Haben Sie noch Fragen oder benötigen Sie weitere Informationen?
Bitte kontaktieren Sie uns.

Kontakt aufnehmen
Portret Kristof Vande Capelle